EP1625138A2 - Monomeres proteges - Google Patents
Monomeres protegesInfo
- Publication number
- EP1625138A2 EP1625138A2 EP04759940A EP04759940A EP1625138A2 EP 1625138 A2 EP1625138 A2 EP 1625138A2 EP 04759940 A EP04759940 A EP 04759940A EP 04759940 A EP04759940 A EP 04759940A EP 1625138 A2 EP1625138 A2 EP 1625138A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- monomer
- alkyl
- hydrogen
- ligand
- ofthe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/044—Pyrrole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/22—Pteridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
Definitions
- FG a and FG a can be "deprotected,” or restored to their original chemical form.
- One example where the protecting group strategy has been utilized to provide functional group reaction selectivity is in the synthesis of oligoribonucleotides from individual ribonucleotide monomer units.
- the ribonucleoside monomers There are several chemically similar sites on the ribonucleoside monomers, e.g. the 2'-, 3'- and 5'- hydroxyl (OH) groups.
- the monomer subunits must be attached in a site-specific manner during RNA synthesis.
- R when taken together with R forms a double bond between the carbon and nitrogen atoms to which they are attached, or R 8 when taken together with R 11 forms a double bond between the carbon and nitrogen atoms to which they are attached;
- R is hydrogen, or when taken together with R forms a double bond between the carbon atoms to which they are attached;
- R 28 is C1-C10 alkyl
- R 29 is a liquid or solid phase support reagent
- Q' is N or CR 45 ;
- R c is C ⁇ -C 6 alkyl
- X 2 can be -OC[OCH 2 CH 2 OC(O)CH 3 ] 2 ;
- R 27 can be CH 3 ;
- R 28 can be (CH 3 ) 2 CH-;
- X5' and X5" can be trimethylsiloxy;
- X5'" can be cyclododecyloxy; and
- B can be:
- X 2 can be -OC[OCH 2 CH 2 OC(O)CH 3 ] 2 ;
- R 27 can be CH 3 ;
- R 28 can be (CH 3 ) 2 CH-;
- X5' and X5" can be trimethylsiloxy;
- X5'" can be cyclododecyloxy; and
- B can be:
- R 3 is hydrogen, halo, C ⁇ -C 4 alkyl, d-C 4 thioalkoxy, NH 2 , NHR , or NR R c ; R 4 when taken together with R 4 forms oxo, or R 4 when taken together with R 5 forms a double bond between the carbon and nitrogen atoms to which they are attached;
- R 10 is hydrogen or is absent
- R 20 is:
- R is hydrogen, or when taken together with R forms a double bond between the carbon atoms to which they are attached; R 22 is hydrogen;
- R d is hydrogen, hydroxy, protected hydroxy, or OOH
- R e is hydrogen, a nitrogen protecting group, or COOR g
- R is hydrogen, or d-C 6 alkyl
- R g is d-C 10 alkyl
- R h is hydrogen, or
- Preferred X5', X5", and X5"' include siloxy and alkoxy or cycloalkoxy.
- the second functionalized hydroxyl group can have the formula:
- halo or halogen refers to any radical of fluorine, chlorine, bromine or iodine.
- cycloalkenyl as employed herein includes partially unsaturated, nonaromatic, cyclic, bicyclic, tricyclic,or polycyclic hydrocarbon groups having 5 to 12 carbons, preferably 5 to 8 carbons, wherein any ring atom can be substituted.
- the cycloalkenyl groups herein described may also contain fused rings. Fused rings are rings that share a common carbon- carbon bond or a common carbon atom (e.g., spiro-fused rings).
- Examples of cycloalkenyl moieties include, but are not limited to cyclohexenyl, cyclohexadienyl, or norbornenyl.
- RNA Modification Database maintained by Pamela F. Crain, Jef Rozenski and James A. McCloskey; Departments of Medicinal Chemistry and Biochemistry, University of Utah, Salt Lake City, UT 84112, USA (RNAmods@lib.med.utah.edu )
- the 5'-O-silyl group can be removed via exposure to fluoride ions, which can include any source of fluoride ion, e.g., those salts containing fluoride ion paired with inorganic counterions e.g., cesium fluoride and potassium fluoride or those salts containing fluoride ion paired with an organic counterion, e.g., a tefraalkylammonium fluoride.
- a crown ether catalyst can be utilized in combination with the inorganic fluoride in the deprotection reaction.
- iRNA agents ofthe invention are particularly useful when targeted to the liver.
- An iRNA agent can be targeted to the liver by incorporation of a monomore derivitzed with a ligand which targets to the liver.
- a liver-targeting agent can be a lipophilic moiety.
- Preferred lipophilic moieties include lipid, cholesterols, oleyl, retinyl, or cholesteryl residues (see Table 1).
- Candidate agents can be evaluated for suitability as described below.
- the 2' modifications can be used in combination with one or more phosphate linker modifications (e.g., phosphorothioate).
- phosphate linker modifications e.g., phosphorothioate
- chimeric oligonucleotides are those that contain two or more different modifications.
- Examples include the mophilino, cyclobutyl, pyrrolidine and peptide nucleic acid (PNA) nucleoside surrogates.
- a preferred surrogate is a PNA surrogate.
- EDTA lipophilic carriers
- lipophilic carriers e.g., cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, l,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine)and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG] 2 , polya
- Terminal modifications can be added for a number of reasons, including as discussed elsewhere herein to modulate activity or to modulate resistance to degradation.
- Terminal modifications useful for modulating activity include modification ofthe 5' end with phosphate or phosphate analogs.
- iRNA agents, especially antisense strands are 5' phosphorylated or include a phosphoryl analog at the 5' prime terminus.
- 5 '-phosphate modifications include those which are compatible with RISC mediated gene silencing.
- X 1 , X 2 , X 3 , and X 4 are each, independently, O or S.
- An iRNA agent can include monomers which have been modifed so as to inhibit degradation, e.g., by nucleases, e.g., endonucleases or exonucleases, found in the body of a subject. These monomers are referred to herein as NRMs, or nuclease resistance promoting monomers or modifications.
- a modification can include the alteration, e.g., replacement, of one or both ofthe non- linking (X and Y) phosphate oxygens and/or of one or more ofthe linking (W and Z) phosphate oxygens.
- Formula X depicts a phosphate moiety linking two sugar/sugar surrogate-base moieties, SB t and SB 2 .
- the population of stereogenic phosphorus atoms may have the Rp configuration and may be substantially free of stereogenic phosphorus atoms having the Sp configuration.
- the phrase "substantially free of stereogenic phosphorus atoms having the R P configuration" means that moieties containing stereogenic phosphorus atoms having the R P configuration cannot be detected by conventional methods known in the art (chiral HPLC, 1H NMR analysis using chiral shift reagents, etc.).
- R a is:
- Preferred carriers have the general formula (R-3) provided below.
- stracture preferred backbone attachment points can be chosen from R 1 or R 2 ; R 3 or R 4 ; or R 9 and R 10 if Y is CR 9 R 10 (two positions are chosen to give two backbone attachment points, e.g., R 1 and R 4 , or R 4 and R 9 .
- Preferred tethering attachment points include R 7 ; R 5 or R 6 when X is CH 2 .
- the carriers are described below as an entity, which can be inco ⁇ orated into a strand.
- OFG 2 is preferably attached directly to one ofthe carbons in the six-membered ring (-OFG 2 in E).
- -(CH ⁇ n OFG 1 and OFG 2 may be disposed in a geminal manner on the ring, i.e., both groups may be attached to the same carbon, e.g., at C-2, C-3, or C-4.
- a targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl- galactosamine, N-acetyl-gulucosamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, biotin, or an RGD peptide or RGD peptide mimetic.
- Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a cancer cell, endothelial cell, or bone cell.
- Ligands may also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl- gulucosamine multivalent mannose, or multivalent fucose.
- the ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF- ⁇ B.
- An RGD peptide moiety can be used to target a tumor cell, such as an endothelial tumor cell or a breast cancer tumor cell (Zitzmann et al, Cancer Res., 62:5139-43, 2002).
- An RGD peptide can facilitate targeting of an iRNA agent to tumors of a variety of other tissues, including the lung, kidney, spleen, or liver (Aoki et al, Cancer Gene Therapy 8:783-787, 2001).
- the RGD peptide will facilitate targeting of an iRNA agent to the kidney.
- the RGD peptide can be linear or cyclic, and can be modified, e.g., glycosylated or methylated to facilitate targeting to specific tissues.
- a glycosylated RGD peptide can deliver an iRNA agent to a tumor cell expressing o B 3 (Haubner et al, Jour. Nucl. Med., 42:326-336, 2001).
- a targeting peptide tethered to an RRMS can be an amphipathic a- helical peptide.
- exemplary amphipathic ⁇ -helical peptides include, but are not limited to, cecropins, lycotoxins, paradaxins, buforin, CPF, bombinin-like peptide (BLP), cathelicidins, ceratotoxins, S. clava peptides, hagfish intestinal antimicrobial peptides (HFIAPs), magainines, brevinins-2, dermaseptins, melittins, pleurocidin, H 2 A peptides, Xenopus peptides, esculentinis-
- helix stabilization residues g., leu, ala, or lys
- a minimum number helix destabilization residues e.g., proline, or cyclic monomeric units.
- the capping residue will be considered (for example Gly is
- the first (or second) monomer forms a canonical Watson-Crick pairing with the base in the complemetary position on the target, or forms a non canonical Watson-Crick pairing having a higher free energy of dissociation and a higher Tm than seen in the paring in the iRNA agent.
- the classical Watson-Crick parings are as follows: A-T, G-C, and A-U.
- Non-canonical Watson-Crick pairings are known in the art and can include, U-U, G-G, G-Atrans, G-Acj S , and GU.
- first and second iRNA agent sequences can also be joined, e.g., by additional bases to form a hai ⁇ in, or by other non-base linkers.
- the target sequence for the second strand has a monomer which will form a canonical Watson-Crick pairing with the monomer selected for the selected position in the second strand.
- the monomer at the selected site in the first sequence includes U (or a modified base which pairs with A), and the monomer in at the selected position in the second sequence is chosen from a monomer which will not pair or which will form a non-canonical pairing, e.g., U or G.
- the iRNA agent can be selected to target a broad spectrum of genes, including any ofthe genes described herein.
- the iRNA agent has an architecture (architecture refers to one or more of overall length, length of a duplex region, the presence, number, location, or length of overhangs, sing strand versus double strand form) described herein.
- the duplex region ofthe iRNA agent will have, mismatches, in addition to the selected or constrained site or sites. Preferably it will have no more than 1, 2, 3, 4, or 5 bases, which do not form canonical Watson-Crick pairs or which do not hybridize. Overhangs are discussed in detail elsewhere herein but are preferably about 2 nucleotides in length. The overhangs can be complementary to the gene sequences being targeted or can be other sequence. TT is a preferred overhang sequence.
- the first and second iRNA agent sequences can also be joined, e.g., by additional bases to form a hai ⁇ in, or by other non-base linkers.
- the monomer at the selected site in the anti-sense stand includes an A (or a modified base which pairs with T), the corresponding monomer in the target is a T, and the sense strand is chosen from a base which will not pair or which will form a noncanonical pair, e.g., G;
- the monomer at the selected site in the anti-sense stand includes a U (or a modified base which pairs with A), the corresponding monomer in the target is an A, and the sense strand is chosen from a monomer wliich will not pair or which will form a non-canonical pairing, e.g., U or G;
- the monomer at the selected site in the anti-sense stand includes a C (or a modified base which pairs with G), the corresponding monomer in the target is a G, and the sense strand is chosen a monomer which will not pair or which will form a non-canonical pairing, e.g., G, A C J S , A t r
- both strands can be modified to optimize the same property, e.g., to increase resistance to nucleolytic degradation, but different modifications are chosen for the sense and the antisense strands, e.g., because the modifications affect other properties as well. E.g., since some changes can affect RISC activity these modifications are chosen for the sense strand.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
Abstract
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46377203P | 2003-04-17 | 2003-04-17 | |
US46566503P | 2003-04-25 | 2003-04-25 | |
US46580203P | 2003-04-25 | 2003-04-25 | |
US46961203P | 2003-05-09 | 2003-05-09 | |
US49398603P | 2003-08-08 | 2003-08-08 | |
US49459703P | 2003-08-11 | 2003-08-11 | |
US50634103P | 2003-09-26 | 2003-09-26 | |
US51024603P | 2003-10-09 | 2003-10-09 | |
US51031803P | 2003-10-10 | 2003-10-10 | |
US51845303P | 2003-11-07 | 2003-11-07 | |
PCT/US2004/007070 WO2004080406A2 (fr) | 2003-03-07 | 2004-03-08 | Compositions therapeutiques |
PCT/US2004/010586 WO2004090108A2 (fr) | 2003-04-03 | 2004-04-05 | Conjugues d'arni |
PCT/US2004/011255 WO2004091515A2 (fr) | 2003-04-09 | 2004-04-09 | Conjugues arni |
PCT/US2004/011822 WO2004094345A2 (fr) | 2003-04-17 | 2004-04-16 | Monomeres proteges |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1625138A2 true EP1625138A2 (fr) | 2006-02-15 |
EP1625138A4 EP1625138A4 (fr) | 2010-06-23 |
Family
ID=35519758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04759940A Withdrawn EP1625138A4 (fr) | 2003-04-17 | 2004-04-16 | Monomeres proteges |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1625138A4 (fr) |
JP (1) | JP4991288B2 (fr) |
AU (1) | AU2004232964B2 (fr) |
CA (1) | CA2522349A1 (fr) |
WO (1) | WO2004094345A2 (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
US8796436B2 (en) | 2003-04-17 | 2014-08-05 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
WO2004094595A2 (fr) * | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | Agents modifiés d'arni |
US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
CA2559161C (fr) | 2004-03-12 | 2013-06-11 | Alnylam Pharmaceuticals, Inc. | Agents arni ciblant le facteur de croissance de l'endothelium vasculaire (vegf) |
AU2005289588B2 (en) | 2004-09-24 | 2011-12-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of ApoB and uses thereof |
US7790878B2 (en) | 2004-10-22 | 2010-09-07 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
US7592322B2 (en) | 2004-10-22 | 2009-09-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
EP1814597A4 (fr) | 2004-11-24 | 2009-04-22 | Alnylam Pharmaceuticals Inc | Modulation arni du gene de fusion bcr-abl et applications associees |
US7361752B2 (en) | 2004-12-14 | 2008-04-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of MLL-AF4 and uses thereof |
DK2230304T3 (da) | 2005-01-07 | 2012-07-16 | Alnylam Pharmaceuticals Inc | IRNA-modulering af RSV og terapeutiske anvendelser deraf |
US7737265B2 (en) | 2005-06-27 | 2010-06-15 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of HIF-1 and therapeutic uses thereof |
WO2007014075A2 (fr) | 2005-07-21 | 2007-02-01 | Alnylam Pharmaceuticals, Inc. | Modulation par l'arni du gene rho-a dans des modeles de recherche |
WO2007053696A2 (fr) | 2005-11-01 | 2007-05-10 | Alnylam Pharmaceuticals, Inc. | Inhibition de la replication du virus de la grippe par interference arn |
EP1993611A4 (fr) | 2006-03-16 | 2013-05-22 | Alnylam Pharmaceuticals Inc | MODULATION ARNi DES TGF-BETA ET USAGES THÉRAPEUTIQUES |
US7718629B2 (en) | 2006-03-31 | 2010-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
KR101141544B1 (ko) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | 에스아이알엔에이 다중 접합체 및 이의 제조방법 |
CN102575252B (zh) | 2009-06-01 | 2016-04-20 | 光环生物干扰疗法公司 | 用于多价rna干扰的多核苷酸、组合物及其使用方法 |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CN108026527B (zh) | 2015-06-15 | 2022-05-10 | Mpeg La有限责任公司 | 确定的多偶联寡核苷酸 |
CA2995995A1 (fr) | 2015-08-24 | 2017-03-02 | Halo-Bio Rnai Therapeutics, Inc. | Nanoparticules polynucleotidiques pour la modulation de l'expression genique et leurs utilisations |
EP3576752A4 (fr) | 2017-02-06 | 2020-12-16 | Mpeg La, LLC | Oligonucléotides multimères ayant une clairance rénale diminuée |
JP2024517903A (ja) | 2021-05-10 | 2024-04-23 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッド | 神経学的状態を治療するための薬学的組成物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996041809A1 (fr) * | 1995-06-09 | 1996-12-27 | The Regents Of The University Of Colorado | Nouveaux groupes de protection et leur utilisation dans un processus ameliore pour la synthese des oligonucleotides |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE795866A (fr) | 1972-02-29 | 1973-08-23 | Basf Ag | Procede de preparation de chlorure de choline solide a ecoulement libre |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
FR2594693B1 (fr) | 1986-02-24 | 1990-01-05 | Farah Nabil | Nouveaux procedes de preparation a partir d'emulsions seches de formes orales solides a liberation modifiee et retardee de leur principes actifs |
SE8701479L (sv) | 1987-04-09 | 1988-10-10 | Carbomatrix Ab | Metod foer inneslutning av biologiskt verksamma preparat samt anvaendning daerav |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
JPH0436233A (ja) | 1990-05-29 | 1992-02-06 | Biomaterial Universe Kk | 生理活性物質含有生体内分解吸収性の徐放性製剤 |
JP3256539B2 (ja) * | 1990-08-28 | 2002-02-12 | エポック・ファーマシューティカルズ・インコーポレイテッド | 連結分子を介する3’―尾分子付オリゴヌクレオチドの固体支持体合成 |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
GB9304620D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Compounds |
JPH07101882A (ja) | 1993-09-30 | 1995-04-18 | Sanei Gen F F I Inc | 水溶性ヘミセルロースを含有する製剤 |
JPH07101881A (ja) | 1993-09-30 | 1995-04-18 | Sanei Gen F F I Inc | 水溶性ヘミセルロースを含有する製剤 |
JP3342550B2 (ja) | 1993-10-01 | 2002-11-11 | 三栄源エフ・エフ・アイ株式会社 | 水溶性ヘミセルロースを含有する製剤 |
JPH07101884A (ja) | 1993-10-01 | 1995-04-18 | Sanei Gen F F I Inc | 水溶性ヘミセルロースを含有する製剤 |
US5652359A (en) * | 1993-12-02 | 1997-07-29 | Epoch Pharmaceuticals, Inc. | Oligonucleotides containing n-methyl thiolated bases having antiviral activity |
JPH07242568A (ja) | 1994-03-04 | 1995-09-19 | Eisai Co Ltd | 苦味隠蔽製剤 |
US5691316A (en) | 1994-06-01 | 1997-11-25 | Hybridon, Inc. | Cyclodextrin cellular delivery system for oligonucleotides |
AU5799996A (en) | 1995-05-26 | 1996-12-11 | Cell Genesys, Inc. | Delivery vehicles comprising stable lipid/nucleic acid compl exes |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
IL151928A0 (en) | 2000-03-30 | 2003-04-10 | Whitehead Biomedical Inst | Rna sequence-specific mediators of rna interference |
RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
-
2004
- 2004-04-16 AU AU2004232964A patent/AU2004232964B2/en not_active Expired
- 2004-04-16 CA CA002522349A patent/CA2522349A1/fr not_active Abandoned
- 2004-04-16 WO PCT/US2004/011822 patent/WO2004094345A2/fr active Application Filing
- 2004-04-16 EP EP04759940A patent/EP1625138A4/fr not_active Withdrawn
- 2004-04-16 JP JP2006513075A patent/JP4991288B2/ja not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996041809A1 (fr) * | 1995-06-09 | 1996-12-27 | The Regents Of The University Of Colorado | Nouveaux groupes de protection et leur utilisation dans un processus ameliore pour la synthese des oligonucleotides |
Non-Patent Citations (7)
Title |
---|
BALKRISHEN BHAT ET AL.: "Deoxyadenosine and Thymidine Bases Held Proximal and Distal by Means of a Covalently-Linked Dimensional Analogue of dA·dT: Intramolecular vs Intermolecular Hydrogen Bonding" J. AM. CHEM. SOC., vol. 118, no. 44, 6 November 1996 (1996-11-06), pages 10744-10751, XP002582187 DOI: 10.1021/ja9618255 * |
GAFFNEY B L ET AL: "The influence of the purine 2-amino group on DNA conformation and stability-II" TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL LNKD- DOI:10.1016/0040-4020(84)85098-X, vol. 40, no. 1, 1 January 1984 (1984-01-01), pages 3-13, XP026629595 ISSN: 0040-4020 [retrieved on 1984-01-01] * |
GROTLI M ET AL: "Solid-phase Synthesis of Branched RNA and Branched DNA/RNA Chimeras" TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL LNKD- DOI:10.1016/S0040-4020(97)00731-X, vol. 53, no. 33, 18 August 1997 (1997-08-18), pages 11317-11346, XP004106005 ISSN: 0040-4020 * |
HELEN M. -P. ET AL.: "Synthesis of a 3-methyluridine phosphoramidite to investigate the role of methylation in a ribosomal RNA hairpin" BIOORGANIC & MEDICINAL CHEMISTRY, vol. 10, no. 2, 27 August 2001 (2001-08-27), pages 325-332, XP002581834 DOI: 10.1016/S0968-0896(01)00283-8 * |
SCARINGE, STEPHEN A.: "Advanced 5'-silyl-2'-orthoester approach to RNA oligonucleotide synthesis" METHODS IN ENZYMOLOGY ( 2000 ), 317 (RNA-LIGAND INTERACTIONS, PT. A), vol. 317, 2000, pages 3-18, XP009133517 ISSN: 0076-6879 * |
See also references of WO2004094345A2 * |
TONGQIAN CHEN ET AL.: "Synthesis and Deprotection of Oligonucleotides under Aprotic Conditions" ORG. LETT., vol. 2, no. 23, 27 October 2000 (2000-10-27), pages 3691-3694, XP002581833 DOI: 10.1021/ol006604p * |
Also Published As
Publication number | Publication date |
---|---|
JP2007525453A (ja) | 2007-09-06 |
WO2004094345A2 (fr) | 2004-11-04 |
AU2004232964B2 (en) | 2011-09-22 |
WO2004094345A8 (fr) | 2016-06-30 |
JP4991288B2 (ja) | 2012-08-01 |
CA2522349A1 (fr) | 2004-11-04 |
AU2004232964A1 (en) | 2004-11-04 |
EP1625138A4 (fr) | 2010-06-23 |
WO2004094345A3 (fr) | 2005-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11312957B2 (en) | Modified iRNA agents | |
AU2004220556B2 (en) | Therapeutic compositions | |
AU2004232964B2 (en) | Protected monomers | |
US10676740B2 (en) | Modified iRNA agents | |
WO2004090108A2 (fr) | Conjugues d'arni | |
US20070179100A1 (en) | Protected monomers | |
AU2013205519B2 (en) | Modified irna agents | |
AU2012202250B2 (en) | Modified iRNA agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051117 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MANOHARAN, MUTHIAH |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100526 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07H 19/044 20060101ALI20100517BHEP Ipc: C07H 23/00 20060101ALI20100517BHEP Ipc: C07C 233/00 20060101ALI20100517BHEP Ipc: C07H 19/02 20060101ALI20100517BHEP Ipc: C07H 7/06 20060101ALI20100517BHEP Ipc: C07H 7/04 20060101ALI20100517BHEP Ipc: C07H 19/056 20060101ALI20100517BHEP Ipc: C07H 19/04 20060101ALI20100517BHEP Ipc: C12N 15/11 20060101AFI20100517BHEP Ipc: C07H 19/14 20060101ALI20100517BHEP Ipc: C07H 21/02 20060101ALI20100517BHEP Ipc: C07H 19/22 20060101ALI20100517BHEP Ipc: C07H 19/167 20060101ALI20100517BHEP Ipc: C12N 15/00 20060101ALI20100517BHEP Ipc: C07D 207/00 20060101ALI20100517BHEP Ipc: C07H 19/052 20060101ALI20100517BHEP Ipc: C07H 19/24 20060101ALI20100517BHEP Ipc: C07H 19/067 20060101ALI20100517BHEP Ipc: C07H 19/23 20060101ALI20100517BHEP |
|
17Q | First examination report despatched |
Effective date: 20101001 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07H 21/02 20060101ALI20160802BHEP Ipc: C07H 19/02 20060101ALI20160802BHEP Ipc: C07H 19/24 20060101ALI20160802BHEP Ipc: C07H 19/04 20060101ALI20160802BHEP Ipc: C07H 23/00 20060101ALI20160802BHEP Ipc: C07H 7/06 20060101ALI20160802BHEP Ipc: C07H 19/14 20060101ALI20160802BHEP Ipc: C07H 7/04 20060101ALI20160802BHEP Ipc: C07H 19/044 20060101ALI20160802BHEP Ipc: C12N 15/00 20060101ALI20160802BHEP Ipc: C07C 233/00 20060101ALI20160802BHEP Ipc: C07H 19/052 20060101ALI20160802BHEP Ipc: C07H 19/23 20060101ALI20160802BHEP Ipc: C12N 15/11 20060101AFI20160802BHEP Ipc: C07H 19/056 20060101ALI20160802BHEP Ipc: C07D 207/00 20060101ALI20160802BHEP Ipc: C07H 19/22 20060101ALI20160802BHEP Ipc: C07H 19/167 20060101ALI20160802BHEP Ipc: C07H 19/067 20060101ALI20160802BHEP Ipc: A61K 31/00 20060101ALI20160802BHEP |
|
INTG | Intention to grant announced |
Effective date: 20160907 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MANOHARAN, MUTHIAH |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170118 |